194 related articles for article (PubMed ID: 37525806)
1. Overt Hypothyroidism Status Post Pfizer-BioNTech Vaccination: A Case Study.
Nandennagari S; Annam P; Naidu N; Vegesna P; Bethala K
Cureus; 2023 Jun; 15(6):e41180. PubMed ID: 37525806
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
3. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
[TBL] [Abstract][Full Text] [Related]
4. Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study.
Aldali J; Meo SA; Al-Khlaiwi T
Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851109
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
[TBL] [Abstract][Full Text] [Related]
6. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
7. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report.
Alshammari F; Abuzied Y; Korairi A; Alajlan M; Alzomia M; AlSheef M
Ann Med Surg (Lond); 2022 Mar; 75():103420. PubMed ID: 35251600
[TBL] [Abstract][Full Text] [Related]
8. Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland.
Paczkowska A; Hoffmann K; Michalak M; Hans-Wytrychowska A; Bryl W; Kopciuch D; Zaprutko T; Ratajczak P; Nowakowska E; Kus K
Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335066
[TBL] [Abstract][Full Text] [Related]
9. An Unusual Presentation of Erythema Multiforme Following the Administration of Pfizer-BioNTech COVID-19 mRNA Vaccine in a Pediatric Patient.
Alghamdi Y; Abdulghani F; Huwait HF; Abdulghani M; Samarkandy SJ
Cureus; 2024 Apr; 16(4):e58450. PubMed ID: 38765345
[TBL] [Abstract][Full Text] [Related]
10. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
[TBL] [Abstract][Full Text] [Related]
11. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Antibody Levels Produced by Pfizer, AstraZeneca, and Sinopharm Vaccination in COVID-19 Patients in Erbil City-Iraq.
Majed SO
Cell Mol Biol (Noisy-le-grand); 2023 Mar; 69(3):103-112. PubMed ID: 37300682
[TBL] [Abstract][Full Text] [Related]
13. The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence.
Rosero-Bixby L
JMIR Public Health Surveill; 2022 May; 8(5):e35054. PubMed ID: 35483079
[TBL] [Abstract][Full Text] [Related]
14. Analyzing COVID-19 Vaccination Side Effects Among the Adult Population in Jeddah, Saudi Arabia.
Alamri T; Anwer F; Butt NS; Alganmi AH; Alotaibi SA; Alzibali KF; Hawsawi HA; Bakarman M; Malik AA
Cureus; 2023 Oct; 15(10):e47136. PubMed ID: 37854474
[TBL] [Abstract][Full Text] [Related]
15. A Case of Acute Viral Pericarditis Complicated With Pericardial Effusion Induced by Third Dose of COVID Vaccination.
Zaki HA; Zahran A; Abdelrahim M; Elnabawy WA; Kaber Y
Cureus; 2022 Jan; 14(1):e21207. PubMed ID: 35165640
[TBL] [Abstract][Full Text] [Related]
16. [Comparative Analyses of IgA Antibody Response of Non-COVID-19 Infected People Over 60 Years Old Following CoronaVac and Pfizer-BioNTech COVID-19 Vaccination].
Yürüker Ö; Yetkin O; Güvenir M
Mikrobiyol Bul; 2023 Apr; 57(2):330-333. PubMed ID: 37067217
[TBL] [Abstract][Full Text] [Related]
17. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
[TBL] [Abstract][Full Text] [Related]
18. Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman.
Alhashim A; Hadhiah K; Al Khalifah Z; Alhaddad FM; Al ARhain SA; Bin Saif FH; Abid A; Al Gamdi O; Alsulaiman F; AlQarni M
Am J Case Rep; 2022 Feb; 23():e934744. PubMed ID: 35136010
[TBL] [Abstract][Full Text] [Related]
19. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine.
Shakoor MT; Birkenbach MP; Lynch M
Am J Kidney Dis; 2021 Oct; 78(4):611-613. PubMed ID: 34280507
[TBL] [Abstract][Full Text] [Related]
20. Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.
Jacobs JW; Booth GS; Adkins BD
Ann Hematol; 2023 Apr; 102(4):955-959. PubMed ID: 36795118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
